Arvinas is a clinical-stage biotechnology company. Co.'s investigational clinical stage programs include: ARV-471, which is an investigational orally bioavailable PROTAC protein degrader designed for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; bavdegalutamide (ARV-110), which is an investigational orally bioavailable PROTAC protein degrader designed for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC; and ARV-766, which is an investigational orally bioavailable PROTAC protein degrader designed to target AR with a different profile than bavdegalutamide, as a potential treatment for men with mCRPC. The ARVN stock yearly return is shown above.
The yearly return on the ARVN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ARVN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|